A number of other equities analysts also recently commented on the company. JPMorgan Chase & Co. downgraded Bayer from an overweight rating to a neutral rating in a report on Wednesday, January 2nd. Deutsche Bank downgraded Bayer from a buy rating to a hold rating in a report on Sunday, March 31st. Zacks Investment Research upgraded Bayer from a strong sell rating to a hold rating in a report on Wednesday, February 13th. Bryan, Garnier & Co downgraded Bayer from a neutral rating to a sell rating in a report on Thursday, March 28th. Finally, Berenberg Bank initiated coverage on Bayer in a report on Monday, April 1st. They set a hold rating for the company. Two analysts have rated the stock with a sell rating, six have assigned a hold rating and two have assigned a buy rating to the stock. Bayer currently has a consensus rating of Hold.
BAYRY traded down $0.56 during midday trading on Monday, hitting $16.80. The stock had a trading volume of 324,552 shares, compared to its average volume of 937,418. The firm has a market cap of $62.74 billion, a P/E ratio of 9.60, a P/E/G ratio of 0.85 and a beta of 0.92. The company has a debt-to-equity ratio of 0.80, a current ratio of 1.59 and a quick ratio of 1.04. Bayer has a 1 year low of $15.67 and a 1 year high of $32.80.
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Price-Sales Ratio
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.